706B5E97-06B6-4401-9934-7CF12FF7F816
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 29.829172141918527
- age_years
- 51
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.608
- INTERFERON_ALPHA_RESPONSE+0.536
- INTERFERON_GAMMA_RESPONSE+0.510
- IL6_JAK_STAT3_SIGNALING+0.485
- TNFA_SIGNALING_VIA_NFKB+0.467
- INFLAMMATORY_RESPONSE+0.434
- COAGULATION+0.385
- ANGIOGENESIS+0.377
- IL2_STAT5_SIGNALING+0.352
- NOTCH_SIGNALING+0.334
Top 10 suppressed
- UV_RESPONSE_DN-0.346
- SPERMATOGENESIS-0.265
- OXIDATIVE_PHOSPHORYLATION-0.257
- G2M_CHECKPOINT-0.239
- KRAS_SIGNALING_DN-0.226
- HEDGEHOG_SIGNALING-0.224
- ANDROGEN_RESPONSE-0.221
- PANCREAS_BETA_CELLS-0.221
- MITOTIC_SPINDLE-0.196
- E2F_TARGETS-0.149
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2W3NC4K1 | Neurofibroma | — | 0.888 |
| 2 | BS_893A91ZM | Neurofibroma | — | 0.880 |
| 3 | SRR810571 | GTEX | — | 0.871 |
| 4 | 575F780D-9288-44CC-A0EA-E28EAD80213B | — | — | 0.844 |
| 5 | SRR8613765 | — | D | 0.835 |
| 6 | SRR817658 | GTEX | — | 0.830 |
| 7 | SRR819346 | GTEX | — | 0.829 |
| 8 | BS_KXMYBQ6N | EPN | EPN Tumor | 0.819 |
| 9 | BS_B7QS4DHK | Schwannoma | — | 0.818 |
| 10 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.608 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.536 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.485 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.467 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.434 | Idelalisib | — uncovered |
| COAGULATION | 0.385 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.377 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.352 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.334 | Inavolisib | — uncovered |
| APOPTOSIS | 0.327 | Idelalisib | — uncovered |
| COMPLEMENT | 0.312 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.297 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.294 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.277 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.236 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.227 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.204 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.202 | Inavolisib | — uncovered |